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Citizen petition: Sexual side effects 
of SSRIs and SNRIs
Division of Dockets Management,
Department of Health and Human Services,
Food and Drug Administration,
5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852, USA
April 23, 2018
The undersigned submits this petition to request the Commissioner of Food and Drugs to immediately 
require the addition of boxed warnings, warnings, precautions, and highlights of prescribing information 
to the product label for all selective serotonin reuptake inhibitor (SSRI) and serotonin-norepinephrine 
reuptake inhibitor (SNRI) products, including branded and generic formulations.
These include, but are not limited to, citalopram (Celexa), desvenlafaxine (Pristiq), duloxetine (Cymbalta), 
escitalopram (Lexapro), fl uoxetine (Prozac), paroxetine (Paxil), sertraline (Zoloft), venlafaxine (Effexor), 
and vortioxetine (Trintellix).
A. Action requested
Require the immediate revision of all SSRI and SNRI product labels (including branded and generic 
formulations) to warn of serious and severe risks, as follows:
1.  Add WARNINGS, PRECAUTIONS, and HIGHLIGHTS OF PRESCRIBING INFORMATION 
to inform that the use of and withdrawal from SSRIs and SNRIs can result in genital anesthesia, 
pleasureless or weak orgasm, delayed or absent orgasm, loss of libido, erectile dysfunction, decreased 
vaginal lubrication, reduced nipple sensitivity, fl accid glans penis during erection, reduced response to 
sexual stimuli, and decreased capacity to experience sexual pleasure.
2.  Add WARNINGS, PRECAUTIONS, and HIGHLIGHTS OF PRESCRIBING INFORMATION to 
inform that the use of and withdrawal from SSRIs and SNRIs can result in persistent genital arousal 
disorder (PGAD).
3.  Add WARNINGS, PRECAUTIONS, HIGHLIGHTS OF PRESCRIBING INFORMATION, and a 
BOXED WARNING to inform that sexual side effects can sometimes persist for years or indefi nitely 
after discontinuation of the drug; they can emerge on treatment and remain afterwards, or emerge or 
worsen when the drug is stopped.
4.  Send all manufacturers of SSRIs and SNRIs a notifi cation letter of the need for a Risk Evaluation and 
Mitigation Strategy Plan to include the following:
i.  Require manufacturers to send a Dear Health Care Provider Letter to psychiatrists, psychologists, 
internists, family practitioners, urologists and endocrinologists that informs the health care providers 
that the drug has serious adverse reactions associated with its use, and poses a signifi cant public 
health concern.
0924-6479/18/$35.00 © 2018 – IOS Press and the authors. All rights reserved
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ii.  Require manufacturers to develop a Medication Guide and Communication Plan to make patients 
aware that the drug has serious risks that could affect the patients’ decision to use or continue to 
use the product.
B. Statement of grounds
SSRI and SNRI antidepressants are well known to cause adverse sexual effects. This was fi rst established 
in healthy volunteer phase 1 trials in the 1980s. Current product labeling warns of disturbances to sexual 
functioning, but these warnings are insuffi cient.
B.1. Genital anesthesia
The ability of a serotonin reuptake inhibitor to reduce genital sensation was identifi ed as far back as 
1991. A study investigated the use of clomipramine as a possible treatment for premature ejaculation [1]. 
Neurophysiological testing was used to assess penile sensory threshold before and after treatment. While 
clomipramine is classed as a tricyclic antidepressant, it is a potent serotonin reuptake inhibitor.
Electrodes were placed on the subject’s penis and very small electric currents were generated until the 
subject could feel the sensation. The current was then decreased until it could no longer be perceived. This 
second fi gure was taken as a measurement of penile sensory threshold. The study found that the drug had 
increased penile sensory threshold from 24.4V before treatment to 30.2V (24%) at the end of 30 days.
In 1999, a similar study involving fl uoxetine found an increase in penile sensory threshold from 4.9mA 
before treatment to 6.1mA (24%) after one month [2]. The fl uoxetine study also had the benefi t of a control 
group (placebo) for whom penile sensory threshold remained unchanged.
In addition, there were multiple case reports of genital anesthesia during the 1990s linked to each of the 
major SSRIs [3-9], including one that involved reduced nipple sensitivity [8]. These date from 1991 to 
2002, and involve the use of fl uoxetine, sertraline, and paroxetine.
Clinical experience suggests that almost everyone who takes an SSRI or SNRI experiences a degree of 
reduced genital sensitivity, often occurring within 30 minutes of taking the fi rst dose. In this sense, almost 
everyone taking a serotonin reuptake inhibitor has altered sexual functioning.
Despite this, and the fact there is an indication for a serotonin reuptake inhibitor for premature ejaculation 
based on this effect (ie. dapoxetine), genital anesthesia remains completely absent from SSRI and SNRI 
product labels.
B.2. Persistent sexual side effects after stopping medication
The common assumption that sexual functioning typically returns to pre-drug baseline after the use of an 
SSRI or SNRI has no clear basis. While clinical experience points to some recovery of function in many 
people, there is no robust evidence that anyone who takes an SSRI or SNRI actually recovers 100% of 
their original genital sensation, sexual response and capacity to experience sexual pleasure. This has never 
been properly investigated.
Pre-medication sexual functioning baselines are rarely taken; there are no queries in any standard sexual 
functioning instruments related to genital numbness or orgasmic anhedonia; there is rarely any follow-up, 
and no-one has systematically asked whether the sexual side effects have resolved — or if anyone has, the 
data has not been published.
Citizen petition: Sexual side effects of SSRIs and SNRIs 137
In 2006, a case report from Bolton et al appeared in the medical literature describing a 26-year-old male 
with persistent sexual side effects following treatment with sertraline [10]. Sexual dysfunction had emerged 
early in treatment, which was continued for around four or fi ve months. Symptoms of genital anesthesia, 
pleasureless orgasm, delayed orgasm, and loss of libido had persisted for six years after withdrawal of 
the drug.
The subject was in no doubt that sertraline was responsible, and the authors of the case report acknowledged 
having been torn, but they tentatively opted for a psychodynamic interpretation of the ongoing symptoms 
because they found nothing in the literature at that time to support the notion of enduring SSRI sexual 
side effects. However, they noted that an enduring pharmacological effect could not be ruled out as an 
alternative explanation.
Three case reports followed from Csoka and Shipko [11]. 
•  A 24-year-old male experienced a persistent loss of libido, and severe tactile insensitivity of his penis, 
chest and abdomen after withdrawal of citalopram.
•  A 27-year-old female who described having a very high libido since puberty, developed a dramatic loss 
of libido, reduced genital and nipple sensitivity, and anorgasmia within three days of using fl uoxetine. 
After discontinuing the drug seven months later, orgasmic capacity returned but at a dramatically 
reduced intensity and with a refractory period of several days. Loss of libido remained and tactile 
sensitivity only partially returned.
•  A 30-year-old male experienced a severe drop in sexual desire, moderate erectile dysfunction, diffi culty 
reaching orgasm with a long refractory time, reduced ejaculate volume, and genital anesthesia within 
four to fi ve days of starting sertraline. The drug was discontinued after fi ve weeks, but the problems 
remained unchanged several years later. Sildenafi l, supplemental testosterone, and herbal remedies 
were tried but without success.
Bahrick described post-SSRI sexual dysfunction (PSSD) as an iatrogenic condition in which sexual side 
effects fail to resolve to baseline after discontinuation of an SSRI/SNRI, often characterized by features 
of genital anesthesia and pleasureless orgasm [12]. She noted that these are not typical features of sexual 
dysfunction, and are not associated with conditions for which antidepressants are prescribed.
The article also drew attention to a 1999 study by Montejo et al which inadvertently appeared to discover 
evidence of post-treatment changes to sexual function [13]. A group of patients who were experiencing 
sexual side effects on an SSRI were switched to the dopaminergic antidepressant, amineptine. Six months 
after the switch, 55% still had at least some type of sexual dysfunction compared to only 4% in the control 
group who were treated with amineptine alone and were not exposed to an SSRI.
In 2007, Kauffman and Murdock reported the case of a 32-year-old female who developed genital 
anesthesia, diminished orgasmic intensity, diffi culty achieving orgasm, and a substantial decrease in libido 
within days of starting citalopram [14]. She described her genital region as “feeling totally numb”. All 
of these diffi culties remained essentially unchanged after discontinuation of the drug, with the subject 
continuing to experience low libido, minimal genital tactile sensation, and orgasmic dysfunction. Physical 
and psychological testing did not reveal a cause.
In 2008, three more cases of persistent sexual dysfunction following SSRIs were reported by Csoka 
et al. [15]. 
•  A 29-year-old male developed severe erectile dysfunction and loss of nocturnal and morning erections 
within 3-4 days of using fl uoxetine, which persisted for 11 years since discontinuing the drug. He was 
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left only able to achieve penetrative sex by using prescribed alprostadil. No psychological or physical 
health problems were found after consultations with two family practice physicians, three urologists, 
two neurologists, an endocrinologist, and a radiologist.
•  A 44-year-old male described persistent loss of libido, genital anesthesia, ejaculatory anhedonia, and 
erectile dysfunction since discontinuing citalopram. No physical or psychological cause was found 
after consultations with several health care professionals, including an endocrinologist, urologist, and 
psychologist.
•  A 28-year-old male developed loss of libido, genital anesthesia, and ejaculatory anhedonia on several 
different SSRIs, which persisted after discontinuing the medication. Numerous tests failed to reveal 
any physical or biochemical abnormalities. Psychological factors were ruled out by three different 
psychiatrists.
A review article published by Bahrick in the same year highlighted the signifi cance of two large placebo 
controlled studies into the use of SSRIs as a treatment for premature ejaculation [16]. The studies by 
Safarinejad and Hosseini [17], and by Arafa and Shamloul [18], found that the ejaculation-delaying 
effects of citalopram and sertraline, respectively, persisted for a signifi cant number of participants at 3- 
and 6-month follow-up after the drugs had been withdrawn. A similar study by Safarinejad involving 
escitalopram has since been published with the same outcome [19].
A study by Tanrikut et al which aimed to investigate the effects of paroxetine on sperm also assessed sexual 
function before, during, and after the fi ve-week treatment period [20]. It was revealed that brief sexual 
function inventory (BSFI) scores for erectile and ejaculatory functions had not returned to baseline four 
weeks after discontinuation of the drug, with 9% of patients complaining of more than mild dysfunction.
Of note, SSRIs have been shown to have adverse effects on semen quality and sperm DNA fragmentation, 
which may be detrimental to male fertility [21-24].
There were published calls for epidemiological studies to investigate the prevalence of PSSD, from 
Kauffman in 2008 [25], and from Farnsworth and Dinsmore in 2009 [26].
In 2011, the US Prozac product information [27] was amended to warn that:
“Symptoms of sexual dysfunction occasionally persist after discontinuation of fl uoxetine treatment.”
In 2012, the Netherlands Pharmacovigilance Center (Lareb) published a report with details of 19 suspected 
cases of PSSD from their database [28]. The fi ndings were subsequently published in the medical literature 
by Ekhart and van Puijenbroek [29]. The drugs involved were paroxetine, sertraline, venlafaxine, 
citalopram, fl uoxetine, fl uvoxamine, and escitalopram. Fifteen reports came from consumers, with the 
remainder from general practitioners, a pharmacist, and a pharmaceutical company. There were 13 male 
subjects and six female, aged from 20 to 59 years. Duration of treatment ranged from 9 days to 10 years, 
and the time since stopping the drug and still experiencing sexual side effects ranged from two months to 
two years.
In 2013, the fi fth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) was 
published. The section on Substance/Medication-Induced Sexual Dysfunction [30] states:
“In some cases, serotonin reuptake inhibitor-induced sexual dysfunction may persist after the agent is 
discontinued.”
Also in 2013, Stinson authored a qualitative study on the impact of persistent sexual side effects of selective 
serotonin reuptake inhibitors after discontinuing treatment [31]. Four male and fi ve female PSSD sufferers 
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were assessed, aged from 22 to 59 years. The drugs involved were citalopram, escitalopram, fl uoxetine, 
paroxetine, and sertraline. Symptoms included genital anesthesia, orgasmic anhedonia, anorgasmia, 
erectile dysfunction, and hypoactive desire. Six of the subjects reported having the condition for over a 
year since stopping the medication, with the longest being three years and nine months.
In 2014, Hogan et al published a study of 120 cases of enduring sexual dysfunction, including 90 involving 
serotonin reuptake inhibitors. The article drew attention to commonalities between the enduring problems 
following SSRIs, SNRIs, fi nasteride, and isotretinoin [32].
Also in 2014, Waldinger et al. offered the fi rst evidence that the genital anesthesia in PSSD may involve 
a peripheral component [33]. A 43-year-old male developed penile anesthesia and scrotum hypesthesia on 
paroxetine which persisted after stopping the drug. He had attempted to assess the level of insensitivity 
by applying Tiger Balm to his penis, but felt nothing except a vague sensation over his scrotum. A small 
degree of tactile sensitivity was regained following treatment with low-power laser irradiation, though 
there was no improvement in sexual responsiveness. It was hypothesized that SSRIs may disrupt the 
normal functioning of transient receptor potential (TRP) ion channels.
In 2015, Ben-Sheetrit et al published a study of 183 possible cases of PSSD including 23 high-probability 
cases from an online survey [34]. The high-probability cases involved fl uoxetine (n = 6), citalopram (n = 5), 
escitalopram (n = 5), venlafaxine (n = 3), sertraline (n = 2), desvenlafaxine (n = 1), and paroxetine (n = 1). 
There were 19 male subjects and four female, aged from 21 to 47 years, all of whom had normal scores 
on depression and anxiety scales, and did not have confounding conditions, medications, or addictive 
substance use. The shortest duration of treatment was 4 days of sertraline. The longest time since stopping 
an SSRI and still experiencing sexual side effects was 16 years.
In 2017, two review articles about PSSD were published by Reisman [35] and Bala et al [36]. Both advised 
that patients should be warned about PSSD when using SSRIs.
In the same year, Muquebil Ali Al Shaban Rodríguez reported the case of a young male with decreased 
libido and erectile dysfunction which had persisted for 12 weeks after withdrawal of paroxetine [37]. 
The subject had no concurrent physical illness, no medication or recreational drug use, and was free of 
affective symptoms. The authors concluded that the previous use of paroxetine was the most likely cause.
A letter (available on request) from Dr. A. Nathwani (Chief Medical Offi cer / Global Head of Medical 
Function / Executive Vice President of Sanofi ), dated December 4, 2017, reported that following an 
internal investigation encompassing a review of the Sanofi  global safety database, available literature, 
pharmacovigilance text books and Sanofi ’s Generic Core Data Sheets (GCDS), it was determined that:
“The cumulative weighted evidence gathered for the mentioned SSRIs was suffi cient to conclude that 
these products could be associated with persistent sexual disorders after treatment discontinuation.”
The “mentioned SSRIs” were fl uoxetine, paroxetine, citalopram, escitalopram, and sertraline.
In a letter (available on request) dated January 15, 2018, the Medicines and Healthcare products Regulatory 
Agency (MHRA) confi rmed that up to January 5, 2018, they had received a total of 1475 UK spontaneous 
suspected ADR reports of sexual dysfunction associated with SSRIs. Of these, 309 indicated that the 
sexual dysfunction persisted after discontinuation of the drug, and in 963 cases it was unknown whether 
the reaction continued after the drug was withdrawn.
In February 2018, a review article about PSSD by Coskuner et al raised concerns about the possibility 
of long-term sexual consequences for people exposed to SSRIs during pregnancy or at a young age [38].
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In May 2018, Healy et al published a study of 300 cases of enduring sexual dysfunction of which 221 were 
after the previous use of serotonin reuptake inhibitors [39]. These were sourced from RxISK’s adverse 
event reporting system.
•  Reports involving serotonin reuptake inhibitors were received from 34 countries. There were 171 male 
subjects and 50 female, aged from 15 to 66 years.
•  The reported drugs were escitalopram (n = 42), citalopram (n = 41), paroxetine (n = 40), sertraline 
(n = 32), fl uoxetine (n = 31), venlafaxine (n = 19), duloxetine (n = 10), fl uvoxamine (n = 2), vortioxetine 
(n = 2), clomipramine (n = 1), and desvenlafaxine (n = 1). Fifteen subjects reported that the duration of 
drug exposure had been less than two weeks.
•  Symptoms included loss of libido (n = 171), erectile dysfunction (n = 147), genital anesthesia (n = 114), 
pleasureless or weak orgasm (n = 86), loss of nocturnal erections (n = 22), vaginal dryness/pain (n = 9), 
and reduced nipple sensitivity (n = 6). Four subjects reported an erectile abnormality in which the glans 
penis remained fl accid when the shaft was erect.
•  Forty-one reports involved adverse sexual effects that either emerged or became signifi cantly worse 
upon stopping a serotonin reuptake inhibitor. This has similarities to antipsychotic-induced tardive 
dyskinesia which can appear on treatment and remain afterwards, or only appear when the medication 
is stopped.
•  Eight subjects reported that the time since stopping a serotonin reuptake inhibitor and still experiencing 
sexual side effects was over 10 years, including one over 20 years.
B.3. Animal studies
Treatment with fl uoxetine has been shown to cause persistent desensitization of 5-HT1A receptors after 
removal of the SSRI in rats [40].
Rodent studies have shown that treatment with SSRIs at a young age resulted in permanently decreased 
sexual behavior in adulthood [41-43], including the presence of long-term neurological changes [41]. 
Maternal exposure to fl uoxetine was also found to impair sexual motivation in adult male mice [44].
In 2016, Simonsen et al published a systematic review of 14 animal studies measuring sexual behavior 
after discontinuation of treatment with SSRIs [45]. It concluded:
“Our results showed substantial and lasting effects on sexual behaviour in rats after exposure to an SSRI 
early in life on important sexual outcomes.”
B.4. Persistent genital arousal disorder (PGAD)
PGAD is a condition involving an uncontrollable and relentless feeling of physiological arousal in the 
genitals, but without any accompanying feeling of sexual desire. It is the mirror image of PSSD. The use 
of SSRIs or SNRIs, and often their withdrawal, has consistently been reported as one of the triggers of the 
condition, which can endure for years after the medication has been discontinued. Desperate women with 
PGAD have resorted to treatment with clitoridectory, pudendal nerve ablation, electroconvulsive therapy 
(ECT), and other drastic measures.
The condition was fi rst described by Leiblum and Nathan in 2001, and was originally called persistent 
sexual arousal syndrome (PSAS) [46].
A letter to the editor of the Journal of Sexual Medicine published in 2005, described a link between 
SSRIs and PGAD [47]. The author attributed the onset of her own condition to the taking and withdrawal 
of SSRIs, and reported that a signifi cant number of people in an online PGAD support group to which 
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she belonged had also used and discontinued SSRIs, namely paroxetine (n = 4), citalopram (n = 5), and 
fl uoxetine (n = 1).
In 2006, Goldmeier, Bell, and Richardson hypothesized that the onset of PGAD following SSRI withdrawal 
may involve an increase in atrial natriuretic peptide [48].
Later that year, Goldmeier and Leiblum noted that within a small study group consisting of physicians and 
PGAD sufferers, several people had reported that their unprovoked genital arousal began when an SSRI 
was discontinued [49].
In 2007, Mahoney and Zarate described a 32-year-old female who developed unrelenting and unwanted 
sensations of genital arousal when her dose of venlafaxine was increased [50]. These sensations remitted 
upon lowering the dose. The authors noted that her symptoms matched the fi ve criteria of PGAD listed by 
Leiblum and Nathan in 2001.
In 2008, fi ve case reports by Leiblum and Goldmeier were published linking SSRIs to the onset of PGAD. 
These involved the use of venlafaxine (n = 3), fl uoxetine, (n = 1), and sertraline (n = 1). All fi ve cases 
involved female subjects. In four of the cases, development of the condition was specifi cally linked to 
withdrawal of the drug [51].
In a 2009 study by Waldinger et al, 13% (n = 3) of patients with PGAD who visited a neurosexology 
outpatient department had been taking SSRIs before onset of the condition, two of whom developed it 
during or shortly after discontinuation of the drug [52].
In 2014, Eibye and Jensen reported the case of a 31-year-old woman who developed PGAD upon 
withdrawal of paroxetine [53]. A pelvic MRI revealed a tarlov cyst, but its size and location could not 
explain the patient’s symptoms. A variety of treatments were tried including ECT, but with only temporary 
improvement.
In 2015, de Magalhães and Kumar described a 57-year-old female who developed PGAD following 
discontinuation of citalopram [54].
A 2017 study by Jackowich et al using a detailed online survey found that 20% (n = 23) of subjects attributed 
the onset of their condition to the previous use of SSRIs [55].
The aforementioned 2018 paper from Healy et al included six reports of PGAD linked to the previous use 
of serotonin reuptake inhibitors [39].
Note that FDA do not currently have codes for PGAD or PSSD.
B.5. Other drugs
FDA updated the product information for fi nasteride products in 2011 to warn of persisting sexual side 
effects after discontinuation of treatment, with further warnings added in 2012 [56]. A similar post-
treatment sexual dysfunction following isotretinoin has been reported in the literature [32, 39].
B.6. Companies
In September 2017, Healy wrote to all companies producing serotonin reuptake inhibitors, drawing their 
attention to the existence of these problems on medicines that have originated with them. Some explored 
the issue of seeking further details on the patients, but have not followed up on this.
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B.7. Conclusion
The data make it clear that SSRIs and SNRIs are potent disruptors of sexual function, and that adverse 
sexual effects can sometimes persist for years or indefi nitely after discontinuation of the drug. In some 
cases, these effects only emerge or worsen when the drug is withdrawn. It also appears that post-treatment 
problems can occur after only a brief exposure to the drug.
At present, the US Prozac product sheet is the only one to mention that sexual side effects can persist after 
the drug is stopped, though the wording is inadequate. The labeling for duloxetine makes no mention of a 
comparable problem, despite being produced by the same company.
PSSD and PGAD can be life-changing, making it diffi cult or impossible to engage in normal intimate 
relationships, or even function in daily life.
Current labeling does not adequately convey the breadth, severity or potentially permanent nature of the 
adverse sexual effects from SSRI and SNRI products. In particular, genital anesthesia and pleasureless 
orgasm should be mentioned specifi cally because these are highly unusual effects and not typical features 
of sexual dysfunction. Neither patients or health care professionals can reasonably be expected to know 
that the impact on sexual functioning could include profound genital numbness and the loss of ability to 
experience pleasure during orgasm.
Across the literature, a number of different terms are used to describe the altered quality of orgasm in 
PSSD, such as pleasureless orgasm, ejaculatory anhedonia, orgasmic anhedonia, and diminished orgasmic 
intensity. However, they are all describing the same phenomenon ie. an orgasm in men and women which 
is markedly lacking in pleasurable sensation, and feels profoundly and abnormally muted to the sufferer, 
such that it is rendered little more than a series of rhythmic muscle contractions in the genital area.
Without adequate warnings about the risk of potentially permanent damage to sexual functioning, 
patients are being deprived of informed consent. It is currently impossible for patients and health care 
professionals to weigh the benefi ts of treatment against the harms. We therefore request that clear warnings 
are immediately added to all SSRI and SNRI products.
C. Environmental impact
We claim categorical exclusion from the environmental assessment requirement under 21 C.F.R §25.31(a), 
as the requested action would not increase the use of the active moiety.
D. Economic impact
We will submit an economic impact analysis upon request, if this is deemed to be necessary.
E. Certifi cation
The undersigned certifi es that, to the best knowledge and belief of the undersigned, this petition includes all 
information and views on which the petition relies, and that it includes representative data and information 
known to the petitioner which are unfavorable to the petition.
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